Literature DB >> 1763328

Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets.

P E Lacy1, O D Hegre, A Gerasimidi-Vazeou, F T Gentile, K E Dionne.   

Abstract

The goal of islet transplantation in human diabetes is to maintain the islet grafts in the recipients without the use of immunosuppression. One approach is to encapsulate the donor islets in permselective membranes. Hollow fibers fabricated from an acrylic copolymer were used to encapsulate small numbers of rat islets that were immobilized in an alginate hydrogel for transplantation in diabetic mice. The fibers were biocompatible, prevented rejection, and maintained normoglycemia when transplanted intraperitoneally; hyperglycemia returned when the fibers were removed at 60 days. Normoglycemia was also maintained by subcutaneous implants that had an appropriately constructed outer surface on the fibers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1763328     DOI: 10.1126/science.1763328

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  34 in total

Review 1.  Alternatives to immunosuppressive drugs in human islet transplantation.

Authors:  Alison Anne Cotterell; Norma Sue Kenyon
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

2.  Alginate: properties and biomedical applications.

Authors:  Kuen Yong Lee; David J Mooney
Journal:  Prog Polym Sci       Date:  2012-01       Impact factor: 29.190

Review 3.  Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain.

Authors:  Esther S O'Sullivan; Arturo Vegas; Daniel G Anderson; Gordon C Weir
Journal:  Endocr Rev       Date:  2011-09-27       Impact factor: 19.871

Review 4.  Non-invasive delivery strategies for biologics.

Authors:  Aaron C Anselmo; Yatin Gokarn; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2018-11-30       Impact factor: 84.694

5.  Comparative cytocompatibility of multiple candidate cell types to photoencapsulation in PEGNB/PEGDA macroscale or microscale hydrogels.

Authors:  Zhongliang Jiang; Kun Jiang; Ralph McBride; John S Oakey
Journal:  Biomed Mater       Date:  2018-10-02       Impact factor: 3.715

Review 6.  Nanotechnology in cell replacement therapies for type 1 diabetes.

Authors:  Alexander U Ernst; Daniel T Bowers; Long-Hai Wang; Kaavian Shariati; Mitchell D Plesser; Natalie K Brown; Tigran Mehrabyan; Minglin Ma
Journal:  Adv Drug Deliv Rev       Date:  2019-02-02       Impact factor: 15.470

7.  A microfluidic-based cell encapsulation platform to achieve high long-term cell viability in photopolymerized PEGNB hydrogel microspheres.

Authors:  Zhongliang Jiang; Bingzhao Xia; Ralph McBride; John Oakey
Journal:  J Mater Chem B       Date:  2016-11-25       Impact factor: 6.331

8.  Macroporous three-dimensional PDMS scaffolds for extrahepatic islet transplantation.

Authors:  Eileen Pedraza; Ann-Christina Brady; Christopher A Fraker; R Damaris Molano; Steven Sukert; Dora M Berman; Norma S Kenyon; Antonello Pileggi; Camillo Ricordi; Cherie L Stabler
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

9.  Lymphoid activation by micro- and macroencapsulated islets during mixed lymphocyte islet culture.

Authors:  T Zekorn; H Entenmann; A Horcher; U Siebers; G Klöck; U Zimmermann; K Federlin; R G Bretzel
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

Review 10.  Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices.

Authors:  Shang Song; Shuvo Roy
Journal:  Biotechnol Bioeng       Date:  2016-01-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.